DeodatiA, FabozziF, MirraG, et al.Long-term thyroid toxicity burden in children who received treatment for high-risk neuroblastoma. Thyroid2026;36(3):259-267; doi: 10.1177/10507256261425684.
2.
ChemaitillyW, CohenLE, Mostoufi-MoabS, et al.Endocrine late effects in childhood cancer survivors. J Clin Oncol2018;36(21):2153-2159; doi: 10.1200/JCO.2017.76.3268.
3.
HendersonT, BardwellJ, KaoP, et al.Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group. Lancet Child Adolesc Health2025;9(11):776-786; doi: 10.1016/S2352-4642(25)00241-X.
4.
De IorisM, LocatelliF. Long-term sequelae in survivors of high-risk neuroblastoma: The price of success. Lancet Child Adolesc Health.2025;9(11):754-755; doi: 10.1016/S2352-4642(25)00274-3.
5.
CohenLE, GordonJH, PopovskyEY, et al.Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems. Bone Marrow Transplant2014;49(4):502-508; doi: 10.1038/bmt.2013.218.
